CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Editas Medicine Inc. (EDIT) on Wednesday reported a loss of $45.4 million in its fourth quarter.
The Cambridge, Massachusetts-based company said it had a loss of 55 cents per share.
The results fell short of Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 39 cents per share.
The genome editing company posted revenue of $30.6 million in the period, which also missed Street forecasts. Four analysts surveyed by Zacks expected $37.9 million.
For the year, the company reported a loss of $237.1 million, or $2.88 per share. Revenue was reported as $32.3 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on EDIT at https://www.zacks.com/ap/EDIT
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。